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Abstract
Invasive breast cancer tends to metastasize to lymph nodes and systemic sites. The management of metastasis has evolved
by focusing on controlling the growth of the disease in the breast/chest wall, and at metastatic sites, initially by surgery
alone, then by a combination of surgery with radiation, and later by adding systemic treatments in the form of chemotherapy,
hormone manipulation, targeted therapy, immunotherapy and other treatments aimed at inhibiting the proliferation of cancer
cells. It would be valuable for us to know how breast cancer metastasizes; such knowledge would likely encourage the development of therapies that focus on mechanisms of metastasis and might even allow us to avoid toxic therapies that are currently
used for this disease. For example, if we had a drug that targeted a gene that is critical for metastasis, we might even be able
to cure a vast majority of patients with breast cancer. By bringing together scientists with expertise in molecular aspects
of breast cancer metastasis, and those with expertise in the mechanical aspects of metastasis, this paper probes interesting
aspects of the metastasis cascade, further enlightening us in our efforts to improve the outcome from breast cancer treatments.
Keywords Genes · Breast cancer evolution · Mitochondrial DNA · Cell clusters · Lymph node and systemic metastasis
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The scientifically based management of breast cancer (BC)
is dependent upon an understanding of the natural history
of the disease. Initially only direct treatment of the diseased
breast was possible, and surgery played a predominant role
well into the middle of the twentieth century [1]. Treatment
by radical mastectomy was offered as an ‘all or nothing’
response; the practitioner could do a drastic operation with
the hope that all the cancer had been removed. Patients and
their families to this day ask the surgeon whether he/she
‘got it all.’ Until fairly recently that also meant removing all
the lymph nodes in the axilla, even when the tumor had not
spread to those nodes, exposing the patient to an uncomfortable series of postoperative complications, including severe
lymphedema of the arm.
The procedures and processes that played out in the imagination of physicians treating patients with BC were based
upon a mechanical/anatomic understanding of metastasis.
In a sense, everything in the metastatic process could be
related to ‘tubes,’ namely, blood vessels and lymphatics,
and their connections in the breast, axilla, and the systemic
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circulation; tumor cells traveled through these vessels to
other parts of the body where they might invade the end
organ, such as the lung, liver, bone or brain, forming metastases. Once vital organs had succumbed to these invasive
tumors the patient would eventually die of the disease.
When radiation [2] was added to the armamentarium of
treatment for BC, it was initially only used for locoregional
management on the superficial chest, axilla and supraclavicular areas, but it later became useful as well for direct treatment of metastases in distant organs. The mechanisms of
metastasis were still not explored beyond the understanding
of an anatomic component; the ‘maps’ of metastasis were
known to involve lymphatics, blood vessels, and end points,
much like geographic maps that indicate roads, rivers, cities,
mountains, coast lines and states.
Systemic treatment for BC, in the form of chemotherapy
and endocrine manipulation, advanced the management
of BC and was based upon a developing understanding of
tumor cell biology, particularly the mechanisms by which
tumor cells proliferated [3]. Proliferation did not explain
why tumor cells metastasized, although cells that landed in
other organs proliferated just like they had in the primary
site in the breast. These systemic treatments were often
directed at symptoms, such as bone pain.
Evolution and revolution in the management of BC has
focused on multidisciplinary treatment and most of the
advances have been directed at decreasing metastasis by
decreasing proliferation; cells that do not proliferate seem
not to metastasize. Many of the large clinical studies of the
past few decades [4] have focused attention on preventing
metastasis by treating the patient with adjuvant therapies,
potentially killing microscopic metastases because that also
improves survival. These advances have been accomplished
knowing where but not how BC metastasizes.
We have begun a new phase in the systemic treatment of
BC by focusing on molecular targets that can be attacked,
such as the well-known HER-2/neu, which is based upon
molecular aberrations in the tumor cells, but not proven to
be involved in how tumors metastasize. Some molecular
targets could be functionally important in how tumor cells
metastasize without necessarily affecting their ability to proliferate. Drugs targeting functionally important molecules
could potentially stop tumors from metastasizing and result
in prolonged survival of the patients.
Studies in animal models and in vitro at the dawn of the
experimental metastasis era [5] showed the importance of
tumor cell invasion into surrounding tissues, with adjusted
biological processes already known in cell biology, such as
chemotaxis, proteolytic enzyme secretion, expression and
de-expression of adhesion molecules, the development of
new blood and lymphatic vessels in and around tumors, and
immune reactivity [6]. Early pharmacologic studies, using
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drugs that target biochemical stages in metastasis, show
some promise but the field is in its infancy.
The guidelines for BC management, based upon high
quality clinical studies have become very dependent upon
molecular markers and on statistical models at predicting
metastasis [7]. For example, the Oncotype DX test looks
at 16 genes, some of which may be functionally important
in metastasis, to predict which estrogen-receptor positive
tumors that have not metastasized to regional lymph nodes
(RLNs) are likely to metastasize to systemic sites [7]. Clinicians frequently use this and other gene studies to decide
which patients might benefit from chemotherapy.
The Henry Ford Cancer Institute Mini Symposium on
the mechanisms of BC metastasis was held in October 2019
in San Francisco as part of the 8th International Cancer
Metastasis Congress. The main objectives of this mini symposium were to look at some recent studies on how tumor
cells behave and travel to systemic sites, either through the
RLN or directly into the systemic circulation at the site of
the original tumor. The more we know about how BC metastasizes at a microscopic, cellular and molecular level, the
more likely we are to develop new, more effective ways of
treating BC.

The potential role of the sentinel node
in systemic metastasis
Timothy P. Padera
The presence of lymph node metastasis (LNM) is associated
with worse clinical outcomes for cancer patients than those
without LNM [8–10]. The question becomes: “Why is this
true?” Is it because LNM is just a biomarker for the aggressiveness of the primary cancer, in which more aggressive
tumors spread to distant sites and drive patient mortality [1,
11]? Or is it that LNMs themselves can drive cancer progression by serving as a source for distant metastases [12–15]?
There is new urgency to address these questions as 4 randomized clinical trials (three breast cancer studies-ASCOGZ0011, IBCSG 23-01, and AMAROS; one melanoma study
MSLT-II) have shown that additional lymph node resection
in patients beyond the sentinel lymph node does not provide
any survival benefit when adjuvant radiation therapy and
systemic therapies are used [16–20]. However, implicit in
this strategy is the potential to leave cancer bearing lymph
nodes in the patient that will require further therapy. Radiation therapy of RLNs has been shown to improve outcomes
(disease-free and cancer-specific survival) in early-stage BC
[21, 22]. Thus, treatment of lymph nodes benefits patients,
highlighting the importance of LNMs in driving cancer
progression.
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To begin to understand how LNMs could be driving cancer progression, we asked whether it was possible for cancer
cells that have colonized lymph nodes to escape the lymph
node and seed distant metastatic sites. The main challenge in
addressing this question is the ability to identify cancer cells
that had been in a lymph node and then were later either circulating in the blood or residing in a distant metastatic site.
To overcome this challenge, we relied on a photoconvertible
fluorescent protein, Dendra2, which when exposed to specific wavelengths of ultraviolet light can change the color of
its emission from green to red [23]. After stably expressing
Dendra2 in 3 murine cancer cell lines (4T1 triple negative
breast carcinoma, B16F10 melanoma and SCCVII squamous
cell carcinoma), each tumor type was grown orthotopically
in syngeneic immunocompetent mice [24]. Once the cancer
cells spontaneously metastasized from the primary tumor
to the lymph node, the primary tumors were surgically
resected. We then exposed only the tumor draining lymph
node to the photoconverting light and were able to switch the
color of the cancer cells in the lymph node from green to red
with an efficiency of about 70%. After this photoconversion,
the only source of red cancer cells in the animal could be
from LNM. We then asked, can we identify red cancer cells
from the lymph node circulating in the blood or in distant
metastatic sites?
First, we collected all the blood from the animals and
using flow cytometry, identified red cancer cells—which
must have been in the lymph node at the time of photoconversion—as well as green cancer cells in the blood of
animals containing photoconverted 4T1 and B16F10 LNMs,
but identified only green cancer cells in the blood of animals containing photoconverted SCVII LNMs [24]. These
data provided the first direct evidence that in some models,
metastatic cancer cells in lymph nodes can escape the node
and enter the blood circulation. Next, we collected the lungs
from these animals, made sections through the whole lung
and used confocal microscopy to spectrally scan through the
tissue. Similar to the blood, we identified red cancer cells, as
well as green cancer cells, in the lungs of animals containing
photoconverted 4T1 and B16F10 LNMs, but identified only
green cancer cells in the lungs of animals containing photoconverted SCVII LNMs [24]. These data provide evidence
that the circulating cancer cells that escape the lymph node
can disseminate to a distant metastatic organ.
To determine if cancer cells can also escape directly
from the primary tumor, we photoconverted a portion of
4T1 primary tumors before they spread to the lymph node
and identified circulating red cancer cells in the blood [24].
Thus, there are two sources of circulating cancer cells: those
directly from the primary tumor and those from the LNM.
Further experiments showed that cancer cells both directly
from the primary tumor and those from spontaneous LNM
can form metastatic lesions in the lungs [24].

The next question we addressed was how cancer cells
escaped the lymph node. There are two possible exit routes.
First, cancer cells could leave via the efferent lymphatic
vessels, heading to the next echelon nodes upstream. Clinically, it is observed that LNM can often be found in secondary draining lymph node beds and cancer cells have
been observed in medullary lymphatic structures in metastatic lymph nodes from extramammary Paget’s disease
[25], making escape through the efferent lymphatic vessels
plausible. However, by performing intravital microscopy
of metastatic lymph nodes, we saw cancer cells migrating
toward and interacting with lymph node blood vessels [24].
We established that cancer cells in our mouse model migrate
and enter lymph node blood vessels, an additional route of
escape for cancer cells out of the lymph node. Finally, looking at a series of LNM from patients with head and neck
squamous cell carcinomas, we identified cancer cells inside
lymph node blood vessels in 7 out of 19 cases [24], confirming that cancer cells in some patients are able to escape the
lymph node through nodal blood vessels.
Our data show it is possible for cancer cells to spontaneously disseminate to lymph nodes and then escape the lymph
node to seed another metastatic site. The work also provides
evidence that one method of escape from the lymph node is
by invasion of the lymph node blood vessels by the cancer
cells. Our work does not exclude other methods of dissemination to distant metastasis (e.g., direct invasion of primary
tumor blood vessels, which we show is also occurring in the
4T1 model) or other methods of escape from the lymph node
(e.g., escape through efferent lymphatic vessels). It also does
not suggest that every patient will have distant dissemination
occurring from metastatic lymph nodes. However, our data
did provide direct evidence for a new route for how cancer
cells can spread throughout the body, one that had long been
hypothesized [13, 26]. Our work was simultaneously corroborated by data from the laboratories of Dontscho Kerjaschki and Michael Sixt, which showed similar findings
using different methods [27].
Other recent work studying LNM in patients also supports the concept that cancer cells can metastasize from
lymph node lesions. In a study of 17 colorectal cancer
patients, Naxerova et al. built phylogenetic trees to relate
the primary tumor, LNMs and distant metastases based on
mutational evolution. In this study 6 out 17 patients showed
LNM with close mutational relationships to distant metastases [28]. Similarly to our mouse data, this study also shows
that some, but not all, patients may have distant metastases seeded by lymph node lesions. In a long-term study of
3329 BC patients that underwent RLN biopsy, Nathanson
et al., show that LNMs are predictive of distant metastases, whereas lymphovascular invasion at the primary site is
not predictive by itself [29]. These data further suggest that
LNM can drive distant cancer progression.
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Our work has shown that it is possible for LNM to spread
further in the body. However, there is currently no actionable
information to identify which patients are at risk for this
occurring. Further research into the molecular and physiological mechanisms that drive this process are needed before
at-risk patients can be identified and interventions designed.
By identifying these mechanisms, we aim to improve outcomes for patients with LNM while balancing the risk of
overtreatment by appropriate patient selection.

The genomic evolution of breast cancer
metastasis
Lucy Yates
Cancer is primarily caused by DNA damage. The transformation from a normal to cancerous phenotype and from
primary to metastatic BC is marked by the accumulation of
genetic changes known as somatic mutations. By applying
evolutionary principles to genomic sequence data, we have
started to uncover the fundamental patterns underlying BC
metastasis.
Whole genome sequencing studies have revealed that BC
genomes are highly abnormal. In a study of 560 primary
BCs, we identified an average of 6214 single base pair substitutions, 665 small insertions and deletions and 140 structural variants per cancer [30]. In a separate study, we found
that the progression from primary tumor to the diagnosis of
distant metastatic disease was accompanied by an increase in
the mutation burden of around a third [31]. Only a tiny fraction of the somatic mutations detected in cancer genomes
alter known cancer genes and act as drivers of cancer progression. The majority of mutations are ‘passengers’ with
no effect cell fitness; however, they provide great statistical
power for identifying mutational signatures and tracing the
evolutionary patterns that underlie cancer metastasis.
Cancer subclones
Breast cancers are composed of multiple genetically related
subclones [32–37].
Subclone composition can vary over space (within
the same tumor mass or across metastatic sites) and time
(sequential samples). All subclones in a cancer are by definition genetically related, having arisen from a single common
ancestor, but individual subclones are distinguished by the
existence of private genetic changes. This may be directly
observed in single cell studies although technical limitations still mean that these are most reliable for measuring
copy number variation rather than point mutations [34, 38].
Subclonal composition can also be inferred indirectly from
bulk tissue samples (that typically consist of thousands of

13

millions of mixed cancer cells and normal cells) using bioinformatic approaches that determine the nature of and cellular
prevalence of genotypes using features such as variant allele
fraction, tumor purity and allele specific copy number information [32, 39]. Multi-region sampling approaches increase
our ability to detect subclonal structure. Recent advances
in low-input material sequencing (of 100 cells or less) are
moving this approach to a new level, providing much higher
resolution of subclone composition in both cancer and normal tissues. In the coming years, we expect these approaches
to continue to provide important insights into how normal
tissue development is subverted during cancer evolution [40,
41].
Different genetic subclones can have different phenotypes and therefore provide the substrate upon which natural
selection may act. Indeed, we and others have demonstrated
that aggressive cancer traits such as invasion, treatment
resistance or metastasis can be mapped back to antecedent subclones earlier in the disease history [31, 32, 41–43].
Understanding how these ill-fated subclones relate and differ to their seemingly well-behaved sisters, within the same
primary tumor, is a major priority in cancer research. The
recent development of a wide range of spatial sequencing
approaches is set to provide critical insights into the spatial arrangement and characterization of individual cancer
subclones [44–46]. Combining these techniques with evolutionary mapping approaches offers an exciting opportunity
to isolate and study the most clinically important subclones
within the tumor environment.
Trees describe cancer evolution
We can use evolutionary or phylogenetic trees, akin to the
‘tree of life’ famously described by Charles Darwin, to represent diagrammatically, the inferred evolutionary relationships between different cancer subclones (Fig. 1). Phylogenetic tree construction starts with two basic assumptions:
mutations can be gained but not lost and each mutation can
only occur once [47]. Although there are caveats to these
assumptions, these can generally be accommodated. Firstly,
we must consider copy number differences between subclones (i.e., where deletions might have ‘lost’ some mutations in one subclone/sample) and secondly, by using as
much of the rich genome-wide mutation data as possible
rather than relying on limited targeted gene panels that only
identify a handful of mutations at best. Using the two principles we can identify ‘clonal’ mutations as those shared
by all cancer cells and form the ‘trunk’ of the phylogenenetic tree (Fig. 1). Mutual exclusivity of mutations identifies subclones from different branches, while co-occurrence
indicates mutations within the same subclone or a direct
lineage. The lengths of branches are typically scaled according to the number of mutations, and therefore, act as a kind
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Fig. 1  Evolutionary or phylogenetic trees provide a map of cancer development and progression. Cancer subclones are represented by different
colored cells with distinct mutation combinations

of molecular clock that allows us to order branching events
in time. Studying the branching patterns that we derive can
then help us to understand how different cancers develop
and progress.
Metastasis seeding cell dissemination timing
The point at which the Metastasis Seeding Cell (MSC)
diverges form the primary tumor has important implications
for the use of adjuvant systemic therapy. Take the example
where 3 driver mutations have accumulated within a primary tumor up to the point where it is diagnosed. A precision medicine treatment plan would have to be based on
the 3 mutations seen in the primary tumor, but we do not
know how representative this is of the potential MSCs at this
time point. In the situation where the MSC left the primary
tumor recently, i.e., the late branching scenario, it is likely
that these cells share the same 3 driver mutations and the
primary tumor can be considered a good proxy. However,
in the case where the MSC departed from the tumor a long
time ago, i.e., an early branching scenario, these cells are
less likely to contain the same driver mutations seen in the
primary tumor and furthermore, they have had significant
time to accumulate novel driver mutations that we will not
be able to detect. The primary tumor in this situation is a
poor proxy, providing inaccurate and incomplete information
about the cancer cells that we wish to eliminate.
When we applied this principle to 17 cases of metastatic
or relapsed BCs, we found that most MSCs diverged from
the primary tumor late in evolution (on average 87% in primary tumor molecular time). This was a phenomenon shared

across distant metastases, local relapses and synchronous
LNM. Importantly, the majority of driver mutations in the
primary tumor were also present in 100% of the cells in
the metastasis indicating that targeted therapies based on
the primary tumor genomic profile would be relevant to the
metastasis.
Some studies appear to contradict our findings, suggesting that cancer cell dissemination occurs, or at least can
occur early—even from pre-invasive lesions [48–52]. Notwithstanding the need to extend our analyses to larger sample series and different BC subtypes, we do suspect that
one potential confounding factor is that these studies have
tended to rely on less robust technologies for inferring clonal
relatedness. Indeed, much of the support for early dissemination is derived from disseminated tumor cell (DTC) studies
that defined bone marrow cells as DTCs based on morphology and cytokeratin expression. Importantly, recent single
cell sequencing of DTCs and exome sequencing/genomewide copy number profiling of the primary tumor revealed
that only a fraction of presumed DTCs are actually clonally
related to the primary tumor [53]. Further work linking these
DTCs to the subsequent metastasis is needed to determine
if real-time characterization could be helpful for treatment
scheduling during the relapse free window.
Future perspectives
Our findings to date have identified that metastases typically
arise from a detectable subclone in the primary tumor. To
date, we have not been able to demonstrate that the driver
mutations that dominate the metastasis are pre-selected in
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the primary tumor. Furthermore, we have had little success
in identifying the anatomical localization of the subclones
that are most closely related to a future metastasis. A critical
question remains to be answered: “Is there something special
about the metastasis seeding subclone?”.
The emergence of spatially resolved approaches, such as
laser capture microscopy with low-throughput sequencing
and in-situ sequencing of somatic mutations, are expected to
allow much closer interrogation of primary tumors and pinpointing of ill-fated subclones [41, 44]. These approaches
will be essential for identifying subclone specific associations with tumor micro-environmental factors that are likely
to be important determinants of subclone fate.

Mitochondrial‑nuclear exchange (MNX)
mice reveal contributions of mitochondrial
genetics to cancer metastasis
Thomas C. Beadnell, Adam D. Scheid, and Danny R.
Welch
Introduction
The ability of cancer cells to metastasize requires coordinated expression of multiple genes [54–64] and the efficiency of metastasis is contributed to by multiple quantitative trait loci (QTL) [65] alleles that influence a trait [66] in
combination with environmental factors.
Because of its comparative size, most studies with QTL
examine the nuclear genome, ignoring the mitochondrial
genome. However, in the context of cancer, mitochondria
are key players, which were first identified by Warburg with
regard to their roles in metabolism [67–69], but the definitive mechanisms by which mitochondrial DNA (mtDNA)
contribute to cancer phenotypes has been understudied and
underappreciated. It is critical to emphasize that mtDNA
polymorphisms are likely metastasis modifiers rather than
drivers per se. mtDNA QTL would combine nuclear and
mitochondrially-encoded genes to regulate cancer severity and metastasis [70–72]. Given the miniscule size of
the mitochondrial genome (~ 16 kb) to the nuclear genome
(~ 3 × 104 kb), could the hypothetical existence of mtDNA
metastasis QTL be reasonable? Despite being relatively
understudied, the answer is that it is likely (reviewed in
[73–75]).
The classic experiment demonstrating the existence of
metastasis QTL in the nuclear genome was performed in the
laboratory of Kent Hunter, who crossed female mice from
multiple Mus musculus strains to male transgenic mice with
the oncogenic polyomavirus middle T antigen (PyMT) under
the control of the mouse mammary tumor virus (MMTV)
promoter (FVB/N-TgN(MMTV-PyMT)) [76]. Critically,
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these mice were made on the FVB/N genetic background
[77]. Crossing inbred strains with FVB/N-TgN(MMTVPyMT) resulted in differential tumor latency and metastatic
burden in the first filial generation [76]. Using backcrosses
and comprehensive genetic screens, his group has identified
metastasis modifiers [78–80], many of which have also been
observed in human BCs [81–83].
However, an alternative interpretation of their data
was recognized because their experimental design
crossed females of those various strains to male FVB/NTgN(MMTV-PyMT) mice. Since mtDNA is maternally
transmitted, the possibility existed that mtDNA could also
be a metastasis modifier QTL. A growing volume of data
implicates mitochondria in cancer and metastasis (reviewed
in [73, 74]). Specifically, Kaori Ishikawa and colleagues
demonstrated that transfer of mitochondria from highly
metastatic cells to poorly metastatic recipient cancer cells
enhanced metastatic potential. A reciprocal experiment also
lowered metastatic efficiency [84].
We began exploring approaches to study contributions of
mtDNA to metastasis. Unfortunately, the unique characteristics of mtDNA presented numerous experimental challenges
(reviewed in [73, 85]). Briefly, mtDNA is present in 100s to
1000s of copies per cell, making alteration of all mtDNA
copies currently impossible even with the most advanced
methods [86]. Therefore, introduction of heterogeneous heteroplasmy would confound effects of the alteration. The use
of cybrids or transmitochondrial mice involves prior exposure to mutagens, which could potentially introduce mutations that would complicate interpretation. Likewise, generation of conplastic mice, while not exposing to mutagenic
agents, involves backcrossing for at least 10 generations to
achieve 99.9% nuclear DNA (nDNA) purity with different
mtDNA composition [87]. While conplastic mice mostly
eliminate disparate nDNA as a confounding variable, the
number of necessary backcrosses increases the likelihood
that nDNA recombination has occurred.
To circumvent the issues associated with the above
approaches, we developed the mitochondrial-nuclear
exchange (MNX) mouse model [88] to assess whether there
are metastasis modifier QTLs in the mitochondrial genome.
Crossing MNX female mice with mammary cancer transgenic mouse models demonstrated a driver-dependent
regulation of metastasis. Moreover, injection of syngeneic
cancer cells into MNX mice revealed non-cell autonomous
contributions of the mitochondrial genome to metastasis.
mtDNA polymorphisms alter immune profiles as well as
other changes to the tumor microenvironment, which affect
metastatic efficiency. Together, these data demonstrate that
mtDNA indeed contains QTL for cancer metastasis.
Generating MNX mice did not involve backcrossing
or mutagen exposure. They were made using micropipette transfer of pronuclei from embryos into enucleated
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cytoplasts from another mouse strain (i.e., having mitochondria from another strain) [88, 89]. The resulting hybrid
embryos transplanted into pseudopregnant mice resulted in
progeny, which are homoplasmic, phenotypically normal
and fertile. The resulting colonies have been maintained for
more than a decade and have been very stable.
Mitochondrial DNA alters metastasis in a cell autonomous
manner
Female MNX mice on the FVB genetic background having FVB mitochondria (FF), BALB/c mitochondria (FB)
or C57BL/6 mitochondria (FC) were crossed with MMTVPyMT mice. The nuclear genomes were identical except
for the transgene. Latency to first tumor formation and
metastasis were measured. FF crosses developed tumors as
expected while time to first tumor was accelerated in the FB
crosses and slowed in FC progeny. Almost identical to the
data from the Hunter crosses, pulmonary metastatic burden
(i.e., cumulative volume of metastases and metastasis size)
differed. The number of metastases arising was relatively
unaffected [90].
Subsequently, the same MNX mouse strains were crossed
to male FVB/N-Tg(MMTVneu) mice, which overexpress
the wild-type Her2/neu oncogene under the control of the
MMTV promoter [91]. Tumor latency and metastases were
quantified. Results in FF and FC progeny were similar to
those seen in the PyMT model. However, Her2 FB mice
developed tumors later and had lower metastatic burden than
FF mice [91]. This contrasted with the PyMT crosses, where
FB mice exhibited more rapid primary tumor formation than
FF mice.
Taken together, these two studies demonstrate that
mtDNA polymorphisms affect both tumorigenicity and
metastasis. The changes are dependent upon contributions
of both the nuclear genome and the mitochondrial genome,
exactly what one would expect for QTL. Additionally,
Brinker and colleagues showed that using male MNX mice
crossed to MMTVneu females (i.e., mtDNA from the MNX
mice would not be inherited in the progeny) resulted in no
difference in the tumor behaviors.
Additional evidence that the mitochondrial genome could
impact tumor formation was obtained by Vivian et al. [92].
Mice unexposed to carcinogen treatments were allowed to
age naturally, and the incidence and location of spontaneous
autochthonous tumors were recorded. Although underpowered for some strains of MNX mice, a tumor protective effect
of C57BL/6 mtDNA was observed.
Since metastasis involves multiple genes to be coordinately expressed and only a very small fraction of those
genes are encoded in the mtDNA, we reasoned that SNP
in mtDNA could influence gene expression in the nuclear
genome. By altering the nuclear epigenome via changes in

cytosine methylation or modifying histones, gene expression
and corresponding phenotypes could be affected. We performed whole genome methylation sequencing coupled with
RNA sequencing and determined that there were selective
changes in the location of methylation in the mouse genome
and that some of those changes occurred concomitant to
changes in gene expression [93]. In a more recent study,
we measured 4 common histone marks using ChIP-Seq and
again found a selectivity in location of histone modifications.
Many of the methylation marks and histone marks are in
similar regions, suggesting that mtDNA somehow dictates
how the nuclear genome operates.
Mitochondrial DNA alters metastasis in a non‑cell
autonomous manner
Although having previously demonstrated that nuclear [87]
and mitochondrial [64, 69] genetics could alter metastatic
efficiency, it was recognized that all cells in F1 progeny
would inherit mtDNA from the MNX mother. We therefore
investigated the role of mtDNA in the tumor microenvironment and its impact on tumor development. Using 2 mammary carcinoma and 2 melanoma cell lines, we were able
to keep the mtDNA constant within the cancer cells and
injected the cells into either WT or MNX mice. Orthotopic
tumor growth was not significantly altered; however, formation of experimental metastasis was significantly affected.
These experiments utilized wild-type C57BL/6 (CC), C3H/
HeN (HH) and reciprocal MNX mice C57BL/6 nDNA:C3H/
HeN mtDNA (CH) and C3H/HeN nDNA:C57BL/6 mtDNA
(HC) into which cells were injected either orthotopically
or into the lateral tail vein. Critically, wild-type mice and
their nuclear-matched MNX counterparts were major histocompatibility matched; so, overt transplant rejection mechanisms were eliminated as an experimental variable. Clearly
the mtDNA in stromal compartments influenced behavior of
tumor cells [94]. The question is: how?
In all mouse strains utilized for the above studies, only
a handful of mtDNA polymorphisms have been identified [71]. Changes have been reported in protein encoding
genes as well as in transfer RNA [71, 92]. Polymorphisms
in mtDNA genes encoding electron transport chain proteins
implicate metabolism and previous studies found oxygen
consumption to be different between MNX strain mammary
tissue [69] and cardiomyocytes [68]. However, parameters
associated with metabolism (i.e., oxygen consumption,
extracellular acidification, and mitochondrial load) showed
no correlation with changes in tumor cell behavior. Metabolomic analyses comparing the MNX mice also identified
metabolite differences among MNX strains. Nothing jumped
out as an explanation for the different tumor cell phenotypes
observed. The caveat to dismissing differences in metabolism as a mechanism for stromal manipulation of metastasis
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is that the measurements were done in vitro and in tissues
that are not necessarily the most appropriate locations of
tumor cells.
A byproduct of electron transport is generation of reactive
oxygen species (ROS). We tested the hypothesis that altered
ROS in MNX mice might be responsible for the changes
in metastatic potential. Using MitoTEMPO, a scavenger for
mitochondria-derived ROS, the metastasis-promoting effects
of C3H/HeN mtDNA were reduced. While the results are
consistent with the hypothesis, reciprocal experiments (i.e.,
increasing ROS in C57 mice) could not be done because of
multiple off-target effects [91].
A key stromal contributor to tumorigenicity and metastasis is the immune system. Based upon linkages between
mitochondrial genetics, metabolism, and observations that
metabolism is closely linked to immune differentiation and
polarization [95], we studied whether baseline immune profiles and functionalities could explain results in the noncell autonomous studies. Most differences between mouse
strain immune profiles were found to be regulated by nDNA.
Interestingly, many of the lymphocyte populations were not
dramatically altered. However, macrophage differentiation
(and perhaps polarization state) was significantly altered by
SNP in the mtDNA [96]. Detailed studies are underway to
refine the changes and to directly test which macrophage
subpopulations are most relevant to the phenotypic changes
reported for tumorigenicity and metastasis.
Relevance and perspective
The co-evolution of mtDNA and nDNA [97] demonstrate
clear communication between the two genomes. Metabolic
adaptations to changing climates encountered by ancient
humans migrating from Africa provided selective pressures
dictating divergence from the original mtDNA genotype

contained in ‘Mitochondrial Eve’ [98]. Those physiological
adaptations mediated by mtDNA haplogroups have played
critical roles in human evolution. Moreover, relevant to this
discussion, they also contribute to disease pathologies and
racial health disparities [73, 99]. Individuals with certain
mtDNA haplogroups have increased predisposition to certain cancers compared to people with other mtDNA haplogroups [85, 90, 91]. Some adaptive advantages in some
mtDNA variants resemble oncogenic mitochondrial functions [100, 101].
Clinicians have long known that patient race/ethnicity contributes to cancer incidence rates and survival. For
instance, triple negative BC is more prevalent in African
American and Hispanic Caucasian women [102, 103] who
exhibit higher proliferation rates, increased angiogenesis
markers, higher grade, higher rates of LNM and worse overall survival compared to non-Hispanic women [104–113].
While economic and modifiable factors contribute to outcome disparities, incidence and progression differences
persist even after controlling for socioeconomic factors
[106, 109–113]. To date, no nuclear genomic explanations
have been found comparing patients from different races
[114–117]. We posit that the impact of contributions from
each QTL that define race are masked by uncontrollable variables in analyses. Use of the MNX model, which isolates
mtDNA as an experimental variable, allowed us to gain a
foothold into the mechanistic underpinnings of mitochondrial contributions to metastasis.
In the context of metastasis, it is critical to remember
that tumor cells encounter multiple different microenvironments throughout their journey from the primary tumor
to distant sites. Our data (Table 1) exploring the roles of
mtDNA in the MNX mice support the notion that mitochondria perform critical functions in the receipt of information
as well as the conveyance of neoplastic cell signals to the

Table 1  MNX mice and corresponding mtDNA-directed phenotypes
MNX mouse
abbreviation

nDNA composition

mtDNA composition

Tumor latency

Metastasis size

No. metastases

nDNA methylation

FB

FVB/NJ

BALB/cJ

FVB/NJ

C57BL/6J

CH

C57BL/6J

C3H/HeN

PyMT:↑
Her2:↑
PyMT:↓
Her2:↑
ND

HC

C3H/HeN

C57BL/6J

ND

ND

PyMT: NS
Her2:↓
PyMT: NS
Her2:↓
↑B16-F10 and
K1735-M2
experimental
metastasis
↓B16-F10 and
K1735-M2
experimental
metastasis

Yes [93]

FC

PyMT [90]:↓
Her2 [91]:↑
PyMT:↑
Her2:↑
ND

MNX, mitochondrial-nuclear exchange; ND, not done; NS, not significant
Phenotypes are relative to wild-type strains with matching nDNA
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microenvironment. While the mitochondrial genome is
small, it leverages the much larger nuclear genome to affect
neoplastic cell behavior. Mitochondria are mediators of outside-in and inside-out cellular communication [118–120].
They sense changes in the microenvironment and signal to
the nucleus the requirement of a cell to adapt. As yet, the
mediators of mitochondrial signaling are poorly defined.
Identifying those signals represents an as yet untapped
opportunity for prognostic information from the mitochondria and therapeutic targets within the mitochondrial
genome. There is currently no direct evidence that mitochondrial genetics play a role in human breast cancer. Efforts
to create Synteny maps between mouse mitochondrial and
human mitochondrial genomes and a comprehensive map of
mtDNA polymorphisms are underway.

Deconstructing collective metastasis:
emergent multicellular mechanisms
supporting metastatic colonization
Emma D. Wrenn and Kevin J. Cheung
A large number of tumor cells reaching distant sites will
die and never grow into a clinically detectable metastasis
[121]. Disseminated tumor cells encounter inhospitable
stromal matrices, cell types, and paracrine signals different from their organ of origin. In addition, they are actively
eliminated by immune cells, such as natural killer (NK) and
T-cells. Diverse mechanisms have been described that enable tumor cells to overcome these barriers: entry into a stem
cell-like state, epithelial-to-mesenchymal and mesenchymalto-epithelial transitions, genetic mutation, and co-option of
the native microenvironment for example [122–124]. Here,
we focus on an emerging mechanism by which cancer cells
increase their chance of success—metastasizing as cohesive
clusters of cells, also known as collective metastasis.
Much research has been conducted on the mechanisms by
which single tumor cells metastasize. However, accumulating studies have shown that tumor cells can also metastasize
as multicellular aggregates, and do so with much higher efficiency than solitary cancer cells [125, 126]. A key foundation for this concept originates from seminal experimental
metastasis studies performed in the mid-twentieth century.
Investigators injected lung cancer, melanoma, and fibrosarcoma tumor cells into mice as either clusters or filtrated single cells [127–129]. In each instance the clusters had significantly greater success forming new metastases. Since then,
a number of studies in different tumor types and metastasis
models have demonstrated greater metastasis formation by
injected clusters compared to single cells [130–133], with
for example ~ 15-fold higher lung metastasis seeding rates
by clusters in pancreatic cancer [134] and up to 500-fold

higher rates in BC [135, 136] compared with equal numbers
of single cells.
These findings are buttressed by recent studies tracing
the clonal composition of spontaneous metastases in mouse
models. Multiple groups have used multi-color fluorescent
tumor cell models [131, 132, 134, 135, 137–139] or deep
sequencing [140, 141] to demonstrate that transplantable
primary tumors produce metastases that are polyclonal, that
is seeded by multiple clones present in the primary tumor.
A large fraction of metastases were found to be polyclonal
in several of these models; 48–53% using BC cell lines
[137], 54% using BC PDXs [131], ~ 80% of large lesions to
the peritoneal wall and diaphragm using KPCX pancreatic
cancer cells [134], and over 97% using the MMTV-PyMT
breast tumor model [135]. A caveat to these experiments is
that polyclonal metastases could arise from serial seeding
by single cells [142]. Importantly, multiple studies have also
conducted experiments excluding large contributions from
serial seeding, which indicates that polyclonal metastases in
their models arise primarily from tumor cell clusters [132,
134, 135, 137].
Deep sequencing studies comparing primary and metastatic genomic alterations have also supported a role for
polyclonal seeding in human tumors. Polyclonal seeding has
been reported in colorectal cancer [143–146], intrahepatic
cholangiocarcinoma [147], gastric cancer [148], and prostate
cancer [149]. Two recent studies of metastatic BC patients
identified polyclonal metastases in 63% to 73% of patients
[150, 151]. This clonal diversity raises the possibility that
multiple subclones in polyclonal metastases could cooperate
to increase one another’s fitness, instead of responding to
selective pressures from the tumor microenvironment purely
on their cell-intrinsic properties. This kind of interclonal
cooperativity has been observed in mouse models of cancer
[139, 152, 153]. But further research is needed to understand
how diverse genetic compositions in tumor cell clusters contribute to different stages of collective metastasis. Importantly, direct isolation of tumor cell clusters (CTCs) from the
blood of metastatic patients has provided further clinical evidence for collective metastasis [154–157]. Moreover, CTC
clusters are correlated with poorer patient prognosis across
the most common cancer types [137, 158–167]. Together
these diverse experimental and clinical studies indicate that
tumor cell clusters are potent metastatic seeds.
Despite these many studies establishing the impact
of cluster-based metastasis, the molecular mechanisms
underpinning their efficient colonization are much less
understood. One possible explanation is physical entrapment; it could be that clusters’ large size simply results
in rapid arrest in the circulation. However, a recent
study demonstrated that patient-derived CTC clusters
in the blood could rearrange into single-file chains,
which survive passage through narrow capillaries [168].
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Additionally, another study in zebrafish models found no
significant difference in the rate of extravasation between
single and clustered CTCs [130]. These findings do not
rule out the importance of physical entrapment. But, as
discussed below, recent studies also show that clustering
of tumor cells alters their properties beyond mechanical
trapping in ways that support metastasis.
The metastatic potential of a single cell can be conceived as a balance of factors promoting or hindering that
cell’s ability to colonize other tissues. But to understand
cluster-based metastasis we have to consider an additional
dimension, the interactions amongst the cells in that cluster.
Indeed, a number of recent studies have coalesced around a
common theme: tumor cell clustering induces global shifts
in key cell states promoting survival, growth, and ultimately
colonization. For instance, clusters may be able to resist
attrition in the critical early stage of colonization (Fig. 2).
Shortly after tail vein injection, tumor cell clusters arrested
in the lungs had lower rates of apoptosis than single BC cells
[137]. Recently, we observed that while both clusters and
single cells were able to reach the lungs immediately after
tail vein injection, clusters persisted while single cells were
mostly cleared within 48 h [136]. Additionally, time lapse
imaging in the presence of an apoptosis biosensor revealed
that clusters generated from 8 of 10 human BC tumor samples were significantly more apoptosis resistant than single
cells in 3-dimensional culture [136]. A recent clinical study
of CTCs from small-cell lung cancer patients also observed a
reduction in apoptosis in CTC clusters vs. single cells [159].
Another study using BC tumor cell clusters from patientderived xenografts found that homophilic CD44 adhesions
promote cluster-based metastasis, possibly through PAK2mediated increases in cell survival [131]. Together, these

suggest that likelihood of survival during colonization is a
key difference between clusters and single tumor cells.
Some of the survival advantage of clusters appears to
depend upon resisting ROS, a critical challenge for disseminating tumor cells [169, 170]. A recent study found that
E-cadherin mitigates TGFb-dependent ROS stress in tumor
cell clusters, facilitating their survival at metastatic sites
[171]. Clusters have also been shown to induce mitophagy
to limit ROS and increase cell survival [172]. Clustering
may play a role in non-apoptotic forms of cell death as well.
Recent reports show that multicellular aggregates are more
resistant to ferroptosis [173, 174], an iron-dependent form of
non-apoptotic cell death characterized by ROS accumulation
[175]. Tumor cell clusters generated Nectin-4 dependent Src
signaling, which buffered against ferroptotic lipid peroxidation [173, 174].
Cell–cell adhesion could also help tumor cell clusters
successfully evade attack from the immune system. Tumor
cell clusters were recently demonstrated to be more resistant to NK cells than single cells via downregulation of NK
cell activating ligands [132]. NK cells play a key role in the
immunosurveillance and targeting of metastasis, and NK
tumor cell infiltration and activation often correlate with better patient prognosis [176–178]. Interestingly, a number of
cell–cell adhesion molecules function as NK cell inhibitory
ligands, suggesting that NK cells may more effectively target
solitary tumor cells or cells that have undergone complete
epithelial mesenchymal transition EMT [132, 179, 180].
Clusters may even utilize the immune system to promote
survival and growth; heterotypic clustering of CTCs with
neutrophils has been found to promote cell cycle entry in
tumor cells [181] and clusters may shift NK cells into a more
metastasis-promoting state [182].

Fig. 2  Clusters resist programmed cell death. Tumor cell clusters have increased survival at metastatic sites through several mechanisms including depletion of reactive oxygen species, resistance to NK cell killing, and pro-survival signals transduced downstream of cell–cell adhesion
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Beyond survival, clustering generates changes in signaling and cell state supportive of metastatic outgrowth.
Tumor cell clusters are more proliferative and more stem
cell-like than single tumor cells [131, 135, 136, 183]. How
does cell–cell contact generate these pro-metastatic states?
An attractive hypothesis is that cell–cell adhesion molecules directly generate pro-proliferative signaling through
cross-talk with cellular signaling pathways that regulate
growth [184]. On the other hand, many studies have shown
that cell–cell adhesion induces contact inhibition, restricting cell proliferation [185, 186]. In fact, the same cell–cell
adhesion molecule can either promote or inhibit metastasis depending on context. For example, E-cadherin is
required for successful metastasis in a mouse model of BC
and promotes cell survival [171]. But in the same mouse
model, E-cadherin activating antibodies inhibit metastasis, suggesting that E-cadherin’s role in metastasis may be
tunable [187]. At present, the balance between pro- and
anti-metastatic signals downstream of cell–cell adhesion
molecules remains unresolved and may be highly contextdependent between different cell types, tumor types, and
model systems.

Cell–cell adhesions can also promote metastasis without
direct intracellular signal transduction. Instead, clustering
can induce 3-dimensional architectural changes that generate
collective signaling. Our group recently characterized nanolumina within tumor cell clusters (Fig. 3)—hollow spaces
between cells, sealed at either end by electron dense cell–cell
junctions [136]. They are often lined by microvilli-like protrusions, which can interdigitate between neighboring cells
and provide high surface area for intercellular interactions.
Nanolumenal junctions were selectively permeable, thereby
controlling the composition of nanolumina and shielding
them from the microenvironment.
Importantly, we found that nanolumina formed sites for
intercellular communication. We identified a growth factor, epigen, which was trafficked into nanolumina where it
achieved concentrations > 5000-fold higher than those outside the cluster. Importantly, epigen suppression profoundly
reduced both primary tumor growth and metastatic outgrowth.
By secreting a growth signal into a shared space, clusters create collective, non-cell autonomous signaling to promote proliferation during metastasis. In this instance, cell–cell adhesions do not directly transduce a signal but instead regulate a

Fig. 3  Tumor cell clusters contain intercellular nanolumina that concentrate signaling molecules. Left, transmission electron microscopy
of an MMTV-PyMT tumor cell cluster. Between tumor cells we
observe intercellular cavities lined by microvilli-like protrusions and

sealed by cell–cell junctions. We find that the growth factor epigen is
trafficked to and concentrated within nanolumina, resulting in cooperative pro-growth signaling during collective metastasis
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signaling molecule’s concentration by trapping it within intercellular cavities. This 3-dimensional topology-dependent collective signaling is an emergent feature of clusters, as it is not
possible in single cells lacking cell–cell adhesion. Our findings
indicate that the physical architecture of a multicellular cluster
provides an additional layer of regulation during metastasis,
and a mechanism for robust intercellular signaling.
Importantly, we also observed nanolumina in freshly isolated human tumor cell cluster samples. Nanolumina with
restricted permeability were also present in an aggressive
subset of basal-like 2 (BL2) triple negative BC cell lines
which highly express epigen, but not in mesenchymal-like
triple negative BC cell clusters. BL2 BCs have poor treatment response and overexpress growth factors and myoepithelial genes, whereas mesenchymal-like BCs overexpress
genes related to EMT and cell motility [188–191]. RNAsequencing analysis demonstrated that BL2 nanoluminacontaining cell lines highly express epithelial genes and
genes associated with branching morphogenesis during
early development. This suggests that epigen expression and
nanolumina may be linked to epithelial identity and could
have a role during epithelial development that is exploited
by metastatic tumor cell clusters.
Treatments are critically needed to effectively eradicate
metastases and suppress the metastatic process [192]. An
understanding of the mechanisms underlying tumor cell
clusters’ metastatic potency could pave the way toward therapies targeting their metastatic advantages. One approach is
to target the adhesion molecules holding clusters together.
Indeed, disrupting cell–cell adhesion can repress metastatic
potential [131, 137, 171, 183, 193]. However, cell–cell adhesion molecules are often highly expressed in normal tissues,
which could narrow the therapeutic window unless tumor
specific properties or activation states are identified. Another
approach is to target the cooperative signals generated by
clusters within nanolumina. However, much remains to be
learned about the optimal strategy to target these collective
signaling compartments in practice. Our finding that BL2
but not mesenchymal-like BCNot cells contain nanolumina
also suggests that the relative contribution and mechanisms
of collective metastasis could differ widely between cancers,
subtypes, and individual patients. Future studies are essential to expand on these mechanistic insights into collective
metastasis, to rigorously assess their relevance to specific
subgroups of patients, and ultimately to translate these findings into the clinic.

Conclusions
Breast cancer metastasis is a complex process requiring
many interacting components, anatomic, cellular and molecular/genetic. Mechanical factors play a part in sentinel lymph
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node metastasis, and breast cancer cells may gain direct
access to the systemic circulation by invasion into veins in
the node. Polyclonal multicellular tumor cell aggregates
metastasize with much higher efficiency than solitary cancer
cells, partly because large size clusters might simply arrest
in the circulation by physical entrapment. DNA studies show
that some breast cancers metastasize to systemic sites without first entering lymph nodes, suggesting the secretion of
gene-induced functional proteins, cytokines and/or peptides,
present in some clones but not others, cause direct invasion
into blood vessels in the primary breast tumor. It is more
likely that tumor cells invade lymphatic rather than blood
vessel capillaries at the primary site.
Identification of activated genes and other molecular
markers that are important in systemic breast cancer metastasis would be valuable to clinicians in many ways. For
example, a more accurate molecular fingerprint of tumor
cells identified by needle biopsy of the primary tumor could
subclassify patients into those who might not benefit from
sentinel node biopsy. Innovation and adaptation will be necessary for continued relevance of SLN biopsy, which will
likely take place in several areas. There would need to be
incremental advances helping to optimize an already good
technique. Other avenues of research could advance SLN
utility even further, including developing more refined criteria for selecting patients for SLN biopsy. Some advances
may make SLN biopsy redundant; for example, we can
imagine non-surgical therapies that will kill tumor in lymph
nodes in which case removing them might become unnecessary. We still don’t know for certain whether removing
the SLN treats breast cancer and that will require further
research.
In our current practice most patients with no clinical
evidence of axillary lymph node metastasis who undergo
lumpectomy for invasive disease are eligible for sentinel
lymph node biopsy. Only one in four patients in this cohort
are found to have node metastasis. This means that 75 of
every 100 patients with negative lymph nodes might safely
avoid the operation of sentinel node biopsy altogether.
Revealing currently unknown molecular markers might help
us identify these patients upfront. Seven in every seventyfive patients without node metastases develop systemic
metastases. More accurate and advanced molecular signatures might allow us to focus adjuvant systemic therapy on
only this small proportion of patients, which would be a
major advance on our current use of commercially available
molecular subtypes used to decide which patients should be
offered chemo, targeted and hormonal therapies. The majority of patients could perhaps safely avoid uncomfortable
systemic and loco-regional treatments without jeopardizing
their chances of survival.
The development of anti-metastatic therapies is an
obvious future direction for researchers who identify
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metastasis-related molecular markers. Hypothesis-directed
research would first need to connect the clinically important molecular markers to the mechanisms of metastasis.
For example, although we know that patients with HER-2/
neu positive breast cancers are at higher risk for systemic
metastasis, there is no direct proof that HER-2/neu is
involved in the process of metastasis. Similarly, triple
negative breast cancer carries a risk of poorer survival
than hormone-receptor rich tumors, but no-one has yet
identified any related molecular or cellular mechanisms to
account for this difference. The relative contributions and
mechanisms of breast cancer metastasis might vary widely
between cancers, subtypes, and individual patients and we
are at the dawn of those discoveries.
The precise biochemical and molecular/genetic signals
that prompt lymphatic or blood vessel invasion, and methods by which tumor cells survive the hazardous journey
through the blood stream, and how exactly those cells settle into their new environment within the body, are still
under investigation but it seems likely that when we discover more details about these mechanisms we will be better able to target steps in metastasis formation. When we
reach those goals we may be able to eliminate metastases
altogether, goals that are both urgent and possible and will
augur a new era of breast cancer treatment.
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